Fecal microbiota transplantation and butyrate attenuate prenatal BPA exposure-mediated endometriosis susceptibility through a gut–immune–metabolic axis

In: Frontiers in Endocrinology · 2026 · vol. 17 · doi:10.3389/fendo.2026.1987816 · W7235623379
Lab / animal OA: gold CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-11-19 ⓘ

Fecal microbiota transplantation and butyrate attenuate prenatal BPA exposure-mediated endometriosis susceptibility by restoring the gut–immune–metabolic axis, reducing intestinal barrier dysfunction, and mitigating systemic inflammatory and metabolic abnormalities.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-11-19 · read from full text ⓘ

This study investigated how prenatal exposure to bisphenol A (BPA) increases susceptibility to endometriosis by disrupting the gut microbiota and reducing butyrate levels in female offspring. Using mouse models and human endometrial cells, researchers found that BPA exposure impaired intestinal barrier integrity and altered metabolic responses, leading to increased lesion burden, while fecal microbiota transplantation and butyrate supplementation partially mitigated these effects. The findings indicate that a functional gut-immune-metabolic axis links developmental environmental exposures to later reproductive disease pathology through mechanisms involving histone lactylation and estrogen signaling. This paper is centrally about endometriosis — specifically examining the role of prenatal BPA exposure and the gut microbiota–butyrate axis in disease susceptibility.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background Prenatal exposure to bisphenol A (BPA) may increase susceptibility to endometriosis, but the persistent biological pathways linking developmental environmental exposure to later reproductive disease remain incompletely understood. We investigated whether alterations in the offspring gut microbiota and microbial metabolites contribute to BPA-associated endometriosis susceptibility and whether restoration of the microbiota–metabolite axis can mitigate this phenotype. Methods Human endometrial epithelial cells (HEECs) and stromal cells (HESCs) were employed to assess cellular responses to BPA, fecal microbiota-conditioned medium (FMT-CM), sodium butyrate (NaB), and exogenous lactate. Female offspring exposed prenatally to BPA were assigned to control/sham, BPA/sham, BPA with control-donor FMT, control with BPA-donor FMT, or BPA with butyrate supplementation groups. Gut microbial composition, intestinal barrier integrity, intestinal butyrate, systemic metabolic and inflammatory responses, and endometriosis-related molecular and lesion phenotypes were evaluated. Results Prenatal BPA exposure was associated with altered gut microbial composition, reduced intestinal butyrate availability, impaired intestinal barrier integrity, systemic inflammatory and metabolic abnormalities, and increased endometriosis-related lesion burden in female offspring. Control-donor FMT partially ameliorated these abnormalities, whereas FMT from BPA-exposed donors partially reproduced the BPA-associated phenotype. In vitro , control donor-derived FMT-CM attenuated several BPA-associated cellular abnormalities, while FMT-CM from BPA-exposed donors showed limited protective activity. Butyrate supplementation also partially improved BPA-associated cellular and offspring phenotypes and reduced lactate accumulation and histone lactylation; these effects were diminished by exogenous lactate. Conclusions Prenatal BPA exposure is associated with persistent disruption of the offspring gut microbiota–butyrate axis, accompanied by intestinal barrier dysfunction and systemic metabolic and inflammatory alterations that may contribute to increased endometriosis susceptibility. The complementary effects of FMT and butyrate support a functional role for microbiota-derived factors, with butyrate representing one potentially important downstream mediator. These findings identify the gut microbiota–metabolite interface as a potential upstream component of environmentally programmed reproductive disease and provide a rationale for further investigation of microbiota-derived interventions.
Full text 52,915 characters · extracted from oa-doi-fallback · 12 sections · click to expand

Abstract

Background: Prenatal exposure to bisphenol A (BPA) may increase susceptibility to endometriosis, but the persistent biological pathways linking developmental environmental exposure to later reproductive disease remain incompletely understood. We investigated whether alterations in the offspring gut microbiota and microbial metabolites contribute to BPA-associated endometriosis susceptibility and whether restoration of the microbiota–metabolite axis can mitigate this phenotype.

Methods

Human endometrial epithelial cells (HEECs) and stromal cells (HESCs) were employed to assess cellular responses to BPA, fecal microbiota-conditioned medium (FMT-CM), sodium butyrate (NaB), and exogenous lactate. Female offspring exposed prenatally to BPA were assigned to control/sham, BPA/sham, BPA with control-donor FMT, control with BPA-donor FMT, or BPA with butyrate supplementation groups. Gut microbial composition, intestinal barrier integrity, intestinal butyrate, systemic metabolic and inflammatory responses, and endometriosis-related molecular and lesion phenotypes were evaluated.

Results

Prenatal BPA exposure was associated with altered gut microbial composition, reduced intestinal butyrate availability, impaired intestinal barrier integrity, systemic inflammatory and metabolic abnormalities, and increased endometriosis-related lesion burden in female offspring. Control-donor FMT partially ameliorated these abnormalities, whereas FMT from BPA-exposed donors partially reproduced the BPA-associated phenotype. In vitro, control donor-derived FMT-CM attenuated several BPA-associated cellular abnormalities, while FMT-CM from BPA-exposed donors showed limited protective activity. Butyrate supplementation also partially improved BPA-associated cellular and offspring phenotypes and reduced lactate accumulation and histone lactylation; these effects were diminished by exogenous lactate.

Conclusions

Prenatal BPA exposure is associated with persistent disruption of the offspring gut microbiota–butyrate axis, accompanied by intestinal barrier dysfunction and systemic metabolic and inflammatory alterations that may contribute to increased endometriosis susceptibility. The complementary effects of FMT and butyrate support a functional role for microbiota-derived factors, with butyrate representing one potentially important downstream mediator. These findings identify the gut microbiota–metabolite interface as a potential upstream component of environmentally programmed reproductive disease and provide a rationale for further investigation of microbiota-derived interventions.

Introduction

Endometriosis is a chronic gynecologic disease characterized by endometrium-like tissue outside the uterus and persistent estrogen-dependent inflammation. It is associated with pelvic pain, reproductive dysfunction, and reduced quality of life (1–3). Retrograde menstruation alone does not explain why only some women develop disease; developmental, genetic, immune, metabolic, and environmental factors may also influence susceptibility (4–6). Bisphenol A (BPA) is an endocrine-disrupting chemical that can affect fetal development and alter endocrine, immune, and metabolic processes during critical developmental windows (7, 8). We previously found that prenatal BPA exposure increased endometriosis susceptibility in female offspring and identified an SF1-associated histone lactylation pathway involved in the resulting phenotype (9). How prenatal exposure leads to persistent postnatal changes remains unclear. The gut microbiota is a plausible link because it helps regulate intestinal barrier integrity, immune homeostasis, and host metabolism, and its metabolites can affect distant tissues (10, 11). Microbial differences have been reported in association with endometriosis (12, 13), but these associations do not establish whether the microbiota contributes to disease susceptibility after prenatal BPA exposure. Butyrate, a microbial product of dietary fiber fermentation, supports epithelial barrier function and modulates immune and metabolic responses (14–18). We therefore proposed the following sequence: prenatal BPA exposure alters the offspring microbiota and reduces butyrate availability; reduced butyrate weakens the intestinal barrier and changes inflammatory and metabolic responses; and these downstream changes favor endometriosis-related pathology. Each link requires experimental evaluation, and the sequence does not exclude other effects of BPA. To test the functional contribution of the microbial community, we used fecal microbiota transplantation (FMT) from control and BPA-exposed donors. We also used sodium butyrate (NaB) supplementation to assess whether restoring this metabolite could attenuate the phenotype (19, 20). The interventions address related but distinct questions: whether a transferable microbial community influences susceptibility and whether butyrate can modify the observed effects. They cannot, by themselves, establish that butyrate mediates every effect of the transplanted microbiota. We examined these questions in female offspring exposed prenatally to BPA and used human endometrial epithelial and stromal cells to assess responses to microbiota-conditioned medium and selected metabolites. We evaluated microbial composition, intestinal butyrate and barrier integrity, systemic inflammatory and metabolic measures, and endometriosis-related outcomes. We hypothesized that control-donor FMT or NaB would attenuate BPA-associated changes, whereas transfer of BPA-associated microbiota to control offspring would reproduce some of them. These experiments were designed to assess a proposed gut–immune–metabolic pathway upstream of, and potentially connected to, the SF1-associated lactylation changes reported previously (9), without assuming that the full causal chain has been established.

Materials and methods

More details for experimental section is shown in Supplementary Data S1 and the primers used in this study are shown on Supplementary Table S1. Reagents and materials The human endometrial epithelial cells (HEEC, #PRI-H-00048) and stromal cells (HESC, #PRI-H-00098) were purchased from ZQXZ Bio (Shanghai, China). Bisphenol A (BPA; #239658; ≥99% purity) and FITC-dextran (#46944) were obtained from Sigma-Aldrich (Shanghai, China). Primary antibodies included Ki-67 (sc-101861) and SF1 (sc-393592) from Santa Cruz Biotechnology; and CYP19A1 (#16554-1-AP) and CLDN1 (#13050-1-AP) from Proteintech; and SOD2 (#13141) from Cell Signaling Technology. Antibodies recognizing histone H3 lactylation at Lys18 (H3K18la; PTM-1406RM), Lys14 (H3K14la; PTM-1414RM), and Lys9 (H3K9la; PTM-1419RM) were obtained from PTM Biolabs (China) (21). In vitro study protocol 1. evaluation of soluble factors in fecal microbiota-conditioned medium HESCs or HEECs were cultured and randomly assigned to four treatment groups: (1) vehicle control (Control), (2) BPA (50 nM), (3) BPA + sterile fecal microbiota-conditioned medium derived from control (CTL) donor mice (BPA+CTL/FMT-CM), and (4) BPA + sterile fecal microbiota-conditioned medium derived from prenatal BPA-exposed donor mice (BPA+BPA/FMT-CM). FMT-CM was prepared by anaerobic homogenization of freshly collected fecal samples in serum-free culture medium, followed by centrifugation and subjected to 0.22-μm membrane filtration to exclude bacterial contaminants while retaining soluble microbial metabolites (22, 23). Following 48 h of treatment, Cells were harvested to evaluate proliferative activity, mitochondrial function, oxidative stress, inflammatory cytokines, intracellular lactate levels, histone lactylation (H3K18la, H3K14la, and H3K9la), and expression of steroidogenic factor 1 (SF1), aromatase (CYP19A1), and estrogen receptor β (ERβ) (14, 24). This experiment was designed to determine whether soluble microbiota-derived factors from healthy donor mice directly mitigate BPA-induced cellular dysfunction. We hypothesized that FMT-CM from control donors would attenuate BPA-induced metabolic, inflammatory, and steroidogenic abnormalities, whereas FMT-CM derived from prenatal BPA-exposed donors would exhibit reduced or absent protective activity. These findings would provide evidence that microbiota-derived soluble factors are sufficient to modulate key cellular features associated with the endometriosis-like phenotype. HESCs were used for the main in vitro experiments (Figures 1–3), and selected findings were confirmed in HEECs (Supplementary Figure S2). Figure 1 Figure 2 Figure 3 In vitro study protocol 2. validation of the butyrate- lactate- histone lactylation mechanism To determine whether butyrate mediates the protective effects of microbiota-derived factors through regulation of lactate metabolism and histone lactylation, HESCs or HEECs were cultured and randomly assigned to four treatment groups: (1) vehicle control (CTL+VEH), (2) BPA (50 nM) + vehicle (BPA+VEH), (3) BPA (50 nM) + sodium butyrate (2 mM) (BPA+NaB), and (4) BPA (50 nM) + sodium butyrate (2 mM) + exogenous sodium lactate (10 mM) (BPA+NaB/Lactate). Cells were collected 48 h after exposure for subsequent analysis of the specified biological endpoints, including cell proliferation, mitochondrial function, oxidative stress, inflammatory cytokine production, intracellular lactate levels, histone lactylation, and gene expression. We hypothesized that BPA exposure increases glycolytic activity and cellular lactate, resulting in enhanced histone lactylation, particularly H3K18la, which promotes SF1/CYP19A1-mediated estrogen signaling, inflammatory activation, and endometriosis-associated cellular dysfunction. Sodium butyrate was expected to suppress glycolytic and lactate-associated changes and reduce histone lactylation, thereby attenuating the downstream cellular phenotype. Conversely, supplementation with exogenous lactate was expected to restore lactate availability and histone lactylation, thereby diminishing or reversing the protective effects of butyrate. This rescue experiment was designed to establish a functional link between butyrate, lactate metabolism, histone lactylation, and the SF1/CYP19A1 signaling axis. HESCs were used for the main in vitro experiments (Figure 2), and selected findings were confirmed in HEECs (Supplementary Figures S4, S5). Gene expression and chromatin analysis RNA was isolated with RNeasy Micro and reverse-transcribed using Omniscript (Qiagen). SYBR Green qPCR (iCycler iQ; 1 µL cDNA) comprised 95 °C for 8 min and 45 cycles of 95 °C, 60 °C, and 72 °C for 10 s each. Validated primers are listed in Supplementary Table S1; expression was calculated using 2^−ΔΔCt with β-actin normalization. ChIP involved formaldehyde fixation (1%, 20 min), glycine quenching (0.1 M), sonication, and antibody/Protein A agarose precipitation of 500 µg chromatin protein. DNA recovered after proteinase K digestion (42 °C, 2 h), crosslink reversal (65 °C, 6 h), and phenol/chloroform extraction was analyzed alongside input DNA by SF1-promoter qPCR (25). Protein and imaging assays Protease inhibitor-supplemented NP-40 lysates underwent 10% SDS-PAGE, PVDF transfer, antibody probing (primary, 1:1,000), and Odyssey infrared quantification (26). For immunofluorescence, cells were fixed in 3.7% formaldehyde (15 min), blocked/permeabilized with 1% BSA/0.2% Triton X-100, and labeled with primary antibodies overnight at 4 °C, fluorescent secondary antibodies (1:500, 1 h), and DAPI. Mitochondrial localization used MitoTracker Red (100 nM, 30 min) and SOD2/Alexa Fluor 488 staining. Blinded ImageJ analysis quantified background-corrected signals and co-localization under identical acquisition settings, averaging at least five fields per sample. Viability, proliferation, and apoptosis MTT reduction was measured after incubation with 0.3 mg/mL MTT (3 h, 25 °C) and overnight dissolution in 10% SDS/0.01 M HCl; absorbance at 560 nm, corrected at 670 nm, was normalized to cell counts (27). DNA synthesis was assessed by [³H]-thymidine incorporation (0.5 µCi/well, 2 h), trichloroacetic acid precipitation, NaOH dissolution, and scintillation counting (28). Soft-agar cultures contained 1,000 cells/dish in 0.3% agarose over a 0.5% base and were evaluated after 30 days in quadruplicate. Caspase-3 activity was determined from Ac-DEVD-AFC cleavage using 50 µg protein and fluorescence at 380/505 nm (29). Oxidative stress, mitochondrial function, and soluble markers ROS-associated fluorescence was measured using CM-H2DCFDA (10 µM, 45 min, 37 °C; 485/530 nm) (29). Commercial assays quantified GSH/GSSG, 3-nitrotyrosine, and MDA; γH2AX was assessed by western blotting relative to H2AX. MDA was measured in clarified plasma and PBS tissue homogenates (1:9 w/v), with results normalized to volume or protein. ATP6/β-actin qPCR assessed relative mitochondrial DNA abundance; luciferin–luciferase measurements quantified protein-normalized ATP (25, 29, 30). Membrane potential was evaluated by TMRE loading (600 nM, 20 min), maintenance in 150 nM dye, and ImageJ analysis at 548/573 nm (30, 31). Lactate was measured with kit #A019-2-1 (Jiancheng; 37 °C, 30 min; 530 nm) against standards (21). IL-1β, IL-6, TNF-α, and MCP-1 were quantified by ELISA measurements at 450/570 nm, with tissue concentrations normalized to BCA-measured protein (32). In vivo mouse protocol. Eight-week-old female C57BL/6J mice were used in this study, all surgical procedures were performed under appropriate anesthesia using inhaled isoflurane (2–3% for induction and 1–2% for maintenance in oxygen). Every effort was made to minimize animal suffering, and at the study endpoint, mice were euthanized by CO2 inhalation in a pre-filled chamber, followed by cervical dislocation to ensure death. Prenatal BPA exposure and offspring generation Females were paired with proven breeder males overnight. The following morning, detection of a vaginal plug was used to define GD0.5. Plug-positive females were then randomly allocated to the control or prenatal BPA treatment group. BPA (50 μg/kg/day) dissolved in 0.1% ethanol/corn oil was administered by oral gavage during the critical developmental window (GD6–GD15), while control dams received vehicle alone. Pups were housed with their respective dams until weaning on PND21. Female progeny were selectively retained for subsequent studies to determine whether maternal BPA exposure influenced later-life susceptibility to endometriosis (9). Syngeneic endometriosis induction At 8 weeks of age, female offspring underwent bilateral ovariectomy (OVX) under inhalational isoflurane anesthesia, followed by a 7-day recovery period. To establish a controlled estrogenic environment, mice received a subcutaneous implantation of a 17β-estradiol (E2) slow-release pellet (0.72 mg, 60-day release). Two days after E2 implantation, syngeneic endometriosis was induced using uterine tissue obtained from age-matched donor C57BL/6J female mice. Donor mice were euthanized during estrus, and the uterine horns were collected under sterile conditions. After removal of surrounding fat and mesentery, the uterine horns were opened longitudinally and cut into approximately 1 mm3 fragments in sterile phosphate-buffered saline (PBS). Each recipient mouse received 8–10 uterine fragments suspended in 200 μL sterile PBS by intraperitoneal injection. The transplanted fragments attached to the peritoneal surface and developed into ectopic endometriotic-like lesions over the subsequent 3–4 weeks. Fecal microbiota transplantation and sodium butyrate intervention After weaning at PND21, female pups were randomly distributed among five experimental cohorts, with nine animals allocated to each group. Group 1: CTL/Sham, Offspring from vehicle-treated dams without microbiota intervention, serving as the physiological baseline control; Group 2: BPA/Sham, Offspring exposed to prenatal BPA without further intervention, serving as the disease model to evaluate BPA-induced microbiota dysbiosis, inflammation, metabolic alterations, and increased endometriosis susceptibility; Group 3: BPA/FMT-CTL, BPA-exposed offspring receiving fecal microbiota transplantation (FMT) from control donors to determine whether restoration of a healthy microbiota can mitigate BPA-induced abnormalities and reduce endometriosis severity; Group 4: CTL/FMT-BPA, Control offspring receiving FMT from BPA-exposed donors to determine whether BPA-associated microbiota alterations are sufficient to transfer disease susceptibility independent of direct BPA exposure; Group 5: BPA/Butyrate, BPA-exposed offspring receiving sodium butyrate supplementation to determine whether butyrate, a key microbiota-derived metabolite, mediates the protective effects associated with microbiota restoration. For FMT experiments, donor mice were generated using the same prenatal BPA exposure protocol described above. Fresh fecal pellets were collected daily from age-matched control or BPA-exposed donor mice under sterile conditions and immediately processed under anaerobic conditions. Fecal samples were homogenized in sterile anaerobic saline (100 mg/mL), the suspension was filtered through a 70-μm nylon mesh to eliminate coarse debris and then delivered to recipient mice by oral gavage at 200 μL per animal per day for 14 consecutive days (33). FMT was initiated after weaning to allow microbiota colonization during early development before endometriosis induction. For sodium butyrate intervention, BPA-exposed offspring received sodium butyrate supplementation through drinking water for 2–4 weeks, following OVX and E2 implantation to evaluate therapeutic reversal (34). This treatment group was included as a mechanistic comparator to distinguish the effects of a specific microbiota-derived metabolite from the broader effects of whole-community microbiota restoration. Together, these five groups allow evaluation of whether prenatal BPA exposure alters the gut microbiota to promote endometriosis susceptibility, whether healthy microbiota can restore the BPA-induced phenotype, whether BPA-associated microbiota can transfer susceptibility to control animals, and whether butyrate alone can reproduce the beneficial effects of microbiota intervention. Gastrointestinal function and microbiota analysis Gastrointestinal function was evaluated by measuring fecal output, intestinal transit, and intestinal permeability using FITC-dextran (35). Feces were obtained immediately before euthanasia and the intestinal microbial community was profiled using 16S rRNA gene sequencing (36). Butyrate levels in fecal samples were determined by targeted GC–MS using an internal standard to enable absolute quantification (37). Gut barrier integrity was assessed from colon tissues by measuring the expression of tight junction proteins, using qPCR and immunofluorescence staining (14). Evaluation of endometriosis lesions Four weeks after endometriosis induction, mice were euthanized under deep anesthesia, and the peritoneal cavity was systematically examined using a stereomicroscope. The incidence, number, anatomical distribution, and gross morphology of ectopic endometriotic lesions were recorded. Individual lesions were carefully excised, photographed, and measured using digital calipers. Lesion dimensions were recorded, and volume was subsequently estimated using the equation V = (L × W²)/2. Endometriosis severity was evaluated based on lesion incidence, lesion number and total lesion volume. Representative lesion specimens were preserved in 4% paraformaldehyde, followed by paraffin embedding for histological analysis, and subjected to immunohistochemistry (IHC) analyses to assess proliferation (Ki-67), estrogen signaling (SF1), and oxidative DNA damage (8-oxo-dG). Molecular and biochemical analyses At the study endpoint, blood, endometriotic lesions, and colon tissues were harvested. Collected tissues were rapidly cryopreserved in liquid nitrogen and kept at −80 °C until further processing. Serum inflammatory cytokines, including IL6, TNFα, IL1β, and MCP1, were quantified by ELISA. Circulating estradiol and estrone levels were measured to evaluate systemic estrogen status. Oxidative stress was assessed by measuring malondialdehyde (MDA), 8-oxo-dG, and the glutathione redox ratio (GSH/GSSG). The expression of estrogen signaling regulators (SF1, CYP19A1, and ERβ) was quantified using qPCR and immunohistochemical analysis. Tissue lactate concentrations were determined using an enzymatic assay. Together, these analyses were designed to determine whether prenatal BPA exposure promotes endometriosis susceptibility through alterations in gut microbiota, butyrate metabolism, intestinal barrier dysfunction, oxidative stress, inflammation, and histone lactylation-associated estrogen signaling, and whether FMT or sodium butyrate intervention can restore these BPA-induced abnormalities. Statistical analysis A computer-generated allocation sequence was used to randomly assign animals to the experimental groups. Investigators responsible for surgical procedures, histological scoring, image quantification, and molecular assays were blinded to group assignments. Results are expressed as the mean ± standard error of the mean (SEM). Data normality was evaluated with the Shapiro–Wilk test (38). Differences across groups were analyzed by one-way analysis of variance (ANOVA), with Tukey’s test used for subsequent pairwise comparisons. A P value below 0.05 was considered statistically significant.

Results

Control FMT-conditioned medium attenuates BPA-induced epigenetic, transcriptional, and oxidative alterations To examine the effects of soluble components in donor-derived FMT-conditioned medium, HESCs were treated with vehicle, BPA, BPA plus sterile FMT-CM from control donors (BPA+CTL/FMT-CM), or BPA plus FMT-CM from prenatal BPA-exposed donors (BPA+BPA/FMT-CM). BPA significantly increased SF1, CYP19A1, and ERβ mRNA and protein expression compared with control cells. These changes were completely or partially attenuated by BPA+CTL/FMT-CM but were minimally affected by BPA+BPA/FMT-CM (Figures 1a–c; Supplementary Figure S1). ChIP-qPCR showed that BPA increased H3K18la and H3K9la enrichment at the SF1 promoter, whereas H3K14la was unchanged. Control FMT-CM partially attenuated the increases in H3K18la and H3K9la enrichment, while BPA-donor FMT-CM had little effect (Figure 1d). BPA also increased 8-oxo-dG and ROS levels and reduced the GSH/GSSG ratio; these changes were partially attenuated by control FMT-CM but not BPA-donor FMT-CM (Figures 1e–h). Similar effects were observed in HEECs, in which control FMT-CM partially attenuated BPA-induced increases in SF1, CYP19A1, and ERβ expression and H3K18la/H3K9la enrichment at the SF1 promoter (Supplementary Figure S2). Control FMT-conditioned medium attenuates BPA-induced mitochondrial dysfunction In HESCs, BPA significantly reduced intracellular ATP, mitochondrial DNA copies, and mitochondrial membrane potential and increased caspase-3 activity compared with control cells. Control FMT-CM partially restored these mitochondrial parameters, whereas BPA-donor FMT-CM had little effect (Figures 3a–d). Consistent with these findings, BPA reduced mitochondrial mass and SOD2 expression, as assessed by MitoTracker Red staining and immunostaining, respectively. These alterations were partially or completely attenuated by control FMT-CM but remained largely unchanged following BPA-donor FMT-CM treatment (Figures 3e, f). Control FMT-conditioned medium attenuates BPA-induced cell proliferation BPA significantly increased DNA synthesis, colony formation, and Ki-67 expression in HESCs. Control FMT-CM partially attenuated these proliferative responses, whereas BPA-donor FMT-CM produced little effect (Figures 4a–d). Figure 4 Control FMT-conditioned medium attenuates BPA-induced inflammatory responses BPA significantly increased secretion of IL6, TNFα, IL1β, and MCP1 by HESCs. These inflammatory responses were partially attenuated by control FMT-CM but were minimally affected by BPA-donor FMT-CM (Supplementary Figures S3a–d). Butyrate attenuates BPA-induced lactate accumulation and histone lactylation enrichment at the SF1 promoter To examine the effects of butyrate and lactate supplementation on BPA-induced cellular changes, HESCs were treated with vehicle, BPA, BPA plus sodium butyrate (BPA+NaB), or BPA plus sodium butyrate and exogenous lactate (BPA+NaB/Lactate). Sodium butyrate partially attenuated BPA-induced increases in SF1, CYP19A1, and ERβ expression, whereas exogenous lactate diminished these effects (Figures 2a, b). Similarly, butyrate reduced BPA-induced H3K18la and H3K9la enrichment at the SF1 promoter, while lactate partially blunted this response (Figure 2c). BPA increased intracellular lactate levels, which were normalized by butyrate and increased again following exogenous lactate supplementation (Figure 2d). Butyrate also partially attenuated BPA-induced ROS accumulation and reductions in the GSH/GSSG ratio, ATP, and mitochondrial DNA copy number; these effects were diminished by lactate supplementation (Figures 2e–h). In HEECs, butyrate similarly attenuated BPA-induced increases in SF1, CYP19A1, and ERβ expression and histone lactylation enrichment at the SF1 promoter, whereas lactate reduced these effects (Supplementary Figure S4). Butyrate also partially reduced BPA-induced secretion of IL6, TNFα, IL1β, and MCP1, with lactate diminishing these effects (Supplementary Figure S5). FMT and butyrate attenuate BPA-associated molecular and inflammatory abnormalities in female mouse offspring We next examined whether FMT or butyrate could attenuate abnormalities associated with prenatal BPA exposure in female mouse offspring. Five groups were analyzed: CTL/Sham, BPA/Sham, BPA/FMT-CTL, CTL/FMT-BPA, and BPA/Butyrate. Compared with CTL/Sham offspring, BPA/Sham offspring exhibited increased SF1 and CYP19A1 mRNA and CYP19A1 protein expression. Both BPA/FMT-CTL and BPA/Butyrate partially attenuated these changes, whereas CTL/FMT-BPA showed changes in the same direction as those observed in BPA/Sham offspring (Figures 5a, b, Supplementary Figure S6). BPA/Sham offspring also showed increased ROS, serum lactate, estradiol, and pro-inflammatory cytokines (IL6, IL1β, TNFα, and MCP1), together with a reduced GSH/GSSG ratio. These abnormalities were partially attenuated by BPA/FMT-CTL and BPA/Butyrate, whereas CTL/FMT-BPA generally showed changes in the same direction as those observed in BPA/Sham offspring (Figures 5c–j). Figure 5 FMT and butyrate improve intestinal barrier function and microbiota-associated abnormalities Prenatal BPA exposure significantly reduced colonic ZO1, OCLN, and CLDN1 mRNA and CLDN1 protein expression compared with CTL/Sham offspring. BPA/FMT-CTL and BPA/Butyrate partially or completely restored these barrier-associated markers, whereas CTL/FMT-BPA showed reductions in the same direction as those observed in BPA/Sham offspring (Figures 6a, b; Supplementary Figure S7). BPA/Sham offspring also exhibited reduced tissue butyrate levels and increased intestinal permeability, as measured by FITC-dextran flux. Both interventions attenuated these abnormalities, while CTL/FMT-BPA showed changes in the same direction as those observed in BPA/Sham offspring (Figures 6c, d). Microbiome analysis showed no significant differences in species richness among groups, but prenatal BPA exposure significantly reduced Shannon diversity. BPA/FMT-CTL and BPA/Butyrate partially restored microbial diversity, whereas CTL/FMT-BPA showed reduced Shannon diversity (Figures 6e, f). At the phylum level, Firmicutes and Bacteroidetes predominated in CTL/Sham offspring. Prenatal BPA exposure was associated with increased relative abundances of Bacteroidetes and Proteobacteria. These changes were partially attenuated by BPA/FMT-CTL and BPA/Butyrate, while CTL/FMT-BPA showed changes in the same direction as those observed in BPA/Sham offspring (Figure 6g; Supplementary Table S2). At the genus level, BPA exposure was associated with reduced relative abundances of Lactobacillus, Faecalibacterium, and Bifidobacterium. These changes were partially attenuated by BPA/FMT-CTL and BPA/Butyrate, while CTL/FMT-BPA showed changes in the same direction as those observed in BPA/Sham offspring (Figure 6h; Supplementary Table S3). Figure 6 FMT and butyrate attenuate prenatal BPA-associated increases in endometriotic lesion burden in mice We next assessed endometriosis-related outcomes in female mouse offspring. Compared with CTL/Sham, BPA/Sham offspring showed increased SF1, CYP19A1, and ERβ expression in endometriotic lesions, together with increased SF1 and Ki-67 expression and 8-oxo-dG formation. BPA/FMT-CTL and BPA/Butyrate partially attenuated these changes, whereas CTL/FMT-BPA showed changes in the same direction as those observed in BPA/Sham offspring (Figures 7a–c). BPA/Sham lesions also exhibited increased MDA and lactate levels and a reduced GSH/GSSG ratio. BPA/FMT-CTL largely normalized these abnormalities, whereas BPA/Butyrate produced partial improvement and CTL/FMT-BPA showed changes toward the values observed in BPA/Sham lesions (Figures 7d–f). Endometriotic lesions were detected in 7/9, 9/9, 8/9, 9/9, and 8/9 mice in the CTL/Sham, BPA/Sham, BPA/FMT-CTL, CTL/FMT-BPA, and BPA/Butyrate groups, respectively. Prenatal BPA exposure significantly increased lesion number and volume compared with CTL/Sham. BPA/FMT-CTL completely attenuated these increases, whereas BPA/Butyrate partially reduced lesion burden. CTL/FMT-BPA also showed increased lesion number and volume, although these increases were smaller than those observed in BPA/Sham offspring (Figures 7g, h). BPA/Sham lesions also showed increased IL6, IL1β, TNFα, and MCP1 levels. These inflammatory responses were partially attenuated by BPA/FMT-CTL and BPA/Butyrate, while CTL/FMT-BPA showed changes in the same direction as those observed in BPA/Sham lesions (Supplementary Figure S8). Figure 7

Discussion

This study examined whether gut microbial and metabolic alterations contribute to increased endometriosis susceptibility following prenatal BPA exposure. BPA exposure was associated with dysbiosis, reduced fecal butyrate, impaired intestinal barrier function, systemic inflammatory and metabolic disturbances, and enhanced endometriosis-related phenotypes. Control-donor FMT partially attenuated these abnormalities, whereas BPA-donor FMT partially reproduced them. Butyrate supplementation produced overlapping protective effects, while in vitro treatment reduced lactate accumulation and histone lactylation, with some effects diminished by exogenous lactate. Together, these findings support a possible microbiota–metabolite contribution to BPA-associated reproductive susceptibility, consistent with reported associations between gut microbial alterations and endometriosis (4, 5). However, they do not establish a single linear causal pathway or identify butyrate as the specific mediator of FMT-associated effects. Gut microbiota and developmental exposure Prenatal BPA exposure was associated with persistent changes in offspring microbial composition, including reduced Lactobacillus, Faecalibacterium, and Bifidobacterium. Previous studies similarly reported altered microbiota, reduced SCFA availability, increased intestinal permeability, and inflammatory disturbances following perinatal or other BPA exposure (39, 40). Reciprocal FMT provides functional evidence that transferable components of donor fecal material may contribute to host abnormalities. Nevertheless, FMT transfers complex microbial communities and associated metabolites, and recipient-dependent engraftment efficiency was not assessed. Consequently, the observed effects cannot be assigned to specific taxa or assumed to reflect equivalent microbial engraftment across recipients. Microbial abundance also does not necessarily indicate metabolic function, which depends on community interactions and cross-feeding (41, 42). The effects of sterile FMT-conditioned medium suggest that soluble fecal components may influence cellular responses, consistent with the biological activities of microbial metabolites (11). Because butyrate concentrations were not quantified in this medium, these effects cannot be attributed specifically to butyrate; other metabolites or soluble factors may contribute. Butyrate and intestinal barrier function Sodium butyrate improved several intestinal, inflammatory, metabolic, and reproductive outcomes. These effects are consistent with established SCFA activities involving epithelial integrity, immune regulation, and cellular metabolism (11, 43, 44). BPA-associated reductions in ZO1, OCLN, and CLDN1 and increased permeability were partially attenuated by control-donor FMT or butyrate. Previous studies reported comparable barrier disturbances following BPA exposure (39, 40), while butyrate enhanced tight-junction assembly through AMP-activated protein kinase in Caco-2 monolayers (14) and exerted immunomodulatory effects through receptor signaling and histone deacetylase inhibition (43). These observations suggest that intestinal homeostasis may contribute to the systemic phenotype, but do not establish that barrier dysfunction directly mediates lesion formation. The greater reduction in lesion growth with FMT than with butyrate may reflect broader microbial or metabolic changes, antibiotic pretreatment, additional soluble products, or differences in intervention exposure. These possibilities were not directly evaluated, and the difference cannot be attributed solely to restoration of butyrate. Metabolic and epigenetic interpretation Our previous study linked prenatal BPA exposure and endometriosis susceptibility to SF1-associated histone lactylation (9). The present findings place this association within a broader microbial and metabolic context: butyrate reduced lactate accumulation and histone lactylation, whereas exogenous lactate diminished some protective effects. These observations are compatible with evidence that lactate-derived histone lactylation connects cellular metabolism with transcriptional regulation (45). However, lactate supplementation affects multiple cellular processes and does not selectively manipulate histone lactylation. Similarly, ChIP-qPCR measures enrichment of lactylation marks at the SF1 promoter but does not establish that these marks are required for SF1 expression or endometriosis-related phenotypes. Butyrate also affects chromatin through histone deacetylase inhibition (43), and its effects may involve metabolic changes, chromatin regulation, or both. Thus, the proposed butyrate–lactate–histone lactylation relationship remains a mechanistic hypothesis requiring selective perturbation and locus-specific validation. Proposed framework and reproductive relevance Collectively, the findings are compatible with a framework in which microbial alterations following prenatal BPA exposure interact with inflammatory and metabolic disturbances and may influence endometrial lactate metabolism, histone lactylation, and reproductive susceptibility (Figure 8). This framework integrates the present observations with literature linking BPA to microbial and inflammatory abnormalities (39, 40) and gut microbial alterations to endometriosis (4, 5). It should be interpreted as a proposed model rather than an established causal sequence. The partial effects of FMT and butyrate suggest multiple contributing processes rather than a single microbial or metabolic determinant. Although postnatal host–microbiome interactions may represent a modifiable component of developmental exposure-associated susceptibility, this possibility remains preclinical. The present study provides no human observational or interventional evidence directly linking prenatal BPA exposure, gut microbiota, butyrate, and endometriosis risk. Figure 8

Limitations

and future perspectives Several limitations constrain interpretation. First, reciprocal FMT does not identify the bacterial taxa responsible for the observed phenotypes or establish a single linear pathway linking prenatal BPA exposure to endometriosis. FMT transfers complex communities and associated metabolites, and recipient-dependent engraftment efficiency was not assessed. Defined microbial consortia, strain-level analyses, longitudinal engraftment assessment, metatranscriptomics, and targeted metabolomics are needed to clarify the relevant microbial functions. Second, butyrate was neither quantified nor standardized in sterile FMT-CM. Its cellular effects therefore cannot be attributed specifically to butyrate, and contributions from other soluble metabolites remain unresolved. Direct metabolite measurement, fractionation, and controlled depletion or supplementation experiments would help distinguish these contributions. Third, molecular causality remains unproven. ChIP-qPCR demonstrates enrichment of histone lactylation marks at the SF1 promoter, while lactate supplementation provides a functional metabolic perturbation; neither establishes that promoter-associated lactylation is necessary for the observed phenotypes. Given the responsiveness of histone lactylation to lactate availability and metabolic state (45), selective manipulation of lactylation and targeted epigenetic approaches are needed to test its contribution independently of broader metabolic effects. Fourth, colonic inflammation was not measured, and a direct causal link between intestinal permeability and lesion formation was not established. Butyrate supplementation began after ovariectomy and estradiol implantation; intervention timings were not compared, and reversal of established lesions was not evaluated. Unmeasured water consumption prevented reliable estimation of butyrate intake and a human-equivalent dose. Local estrogen production and unmeasured circulating or lesion-level estradiol may also have influenced the findings despite standardized exogenous estrogen administration. Finally, the commercial primary human endometrial epithelial and stromal cells were obtained from donors whose endometriosis status was unknown. These models cannot establish disease-specific responses and require validation in patient-derived cells from well-characterized endometriosis and control subjects. All mechanistic findings were obtained from animal and in vitro models. Human studies incorporating documented prenatal BPA exposure, microbiome and metabolite profiling, and reproductive outcomes are needed to assess whether the proposed relationships apply to human endometriosis.

Conclusion

Our findings suggest that gut microbial and metabolic alterations may contribute to increased endometriosis susceptibility following prenatal BPA exposure. Reciprocal FMT and butyrate supplementation provide preclinical support for a possible gut–immune–metabolic contribution, but do not identify specific causal taxa, establish butyrate as the mediator of FMT-CM effects, or demonstrate that SF1-promoter histone lactylation is required for the phenotype. Targeted microbial, metabolic, and epigenetic experiments, together with validation in well-characterized patient-derived cells and human studies, are needed to clarify these relationships and their translational relevance. Statements Data availability statement The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author. Ethics statement The animal study protocol was approved by the Ethical Committee of The Eighth Affiliated Hospital of Sun Yat-Sen University (#202600008). The study was conducted in accordance with the local legislation and institutional requirements. Author contributions DL: Writing – original draft, Investigation, Validation. TZ: Writing – original draft, Methodology, Investigation. XL: Validation, Writing – original draft, Methodology. SL: Writing – original draft, Data curation, Validation. ZH: Writing – original draft, Investigation, Formal analysis. LH: Resources, Writing – original draft, Investigation. PY: Writing – original draft, Supervision, Conceptualization, Project administration, Validation, Writing – review & editing, Methodology, Data curation. LZ: Conceptualization, Validation, Supervision, Resources, Funding acquisition, Writing – review & editing, Project administration. Funding The author(s) declared that financial support was received for this work and/or its publication. This study was kindly supported by Sun Yat-Sen Eighth Affiliated Hospital Clinical Research Project #: PY-2024-002. Conflict of interest The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Generative AI statement The author(s) declared that generative AI was not used in the creation of this manuscript. Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us. Publisher’s note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Supplementary material The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2026.1987816/full#supplementary-material Abbreviations BPA, Bisphenol A; ChIP, chromatin immunoprecipitation; CLDN1, claudin-1; CYP19A1, cytochrome P450 family 19 subfamily A member 1 (aromatase); ERβ, estrogen receptor β; FMT, fecal microbiota transplantation; IHC, immunohistochemistry; IL6, interleukin-6; IL1β, interleukin-1β; MCP1, monocyte chemoattractant protein-1; NaB, sodium butyrate; OCLN, occluding; PBMC, peripheral blood mononuclear cells; ROS, reactive oxygen species; SF1, steroidogenic factor-1; TNFα, tumor necrosis factor α; ZO1, zonula occludens-1.

References

1 PatzkowskyK. Rethinking endometriosis and pelvic pain. J Clin Invest. (2021) 131:e54876. doi: 10.1172/jci154876 2 YangYLaiHLiZZhangJ. Endometriosis and aspirin: a systematic review. Front Endocrinol (Lausanne). (2024) 15:1409469. doi: 10.3389/fendo.2024.1409469 3 ZondervanKTBeckerCMMissmerSA. Endometriosis. N Engl J Med. (2020) 382:1244–56. doi: 10.1056/nejmra1810764 4 LeonardiMHicksCEl-AssaadFEl-OmarECondousG. Endometriosis and the microbiome: a systematic review. BJOG. (2020) 127:239–49. doi: 10.1111/1471-0528.15916 5 WeberISienkoAUrbanASzwedCCzajkowskiKBastaPet al. Relationship between the gut microbiome and endometriosis and its role in pathogenesis, diagnosis, and treatment: a systematic review. Ginekol Pol. (2023). doi: 10.5603/gpl.97581 6 CrestaniBUccellaSPavoneMBarraFBaggioSCeccaroniMet al. Gut microbiota alterations and reproductive tract dysbiosis in endometriosis: a systematic review. Med (Kaunas). (2026) 62:351. doi: 10.3390/medicina62020351 7 SiracusaJSYinLMeaselELiangSYuX. Effects of bisphenol A and its analogs on reproductive health: a mini review. Reprod Toxicol. (2018) 79:96–123. doi: 10.1016/j.reprotox.2018.06.005 8 GolubMSWuKLKaufmanFLLiLHMoran-MessenFZeiseLet al. Bisphenol A: developmental toxicity from early prenatal exposure. Birth Defects Res B Dev Reprod Toxicol. (2010) 89:441–66. doi: 10.1002/bdrb.20275 9 LiuXFuYHuangLLiDYaoPZengL. Prenatal bisphenol A exposure reprograms SF1-lactylation pathways to promote endometriosis susceptibility. iScience. (2026) 29:115608. doi: 10.1016/j.isci.2026.115608 10 GuoCZhangC. Role of the gut microbiota in the pathogenesis of endometriosis: a review. Front Microbiol. (2024) 15:1363455. doi: 10.3389/fmicb.2024.1363455 11 MannERLamYKUhligHH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol. (2024) 24:577–95. doi: 10.1038/s41577-024-01014-8 12 SvenssonABrunkwallLRothBOrho-MelanderMOhlssonB. Associations between endometriosis and gut microbiota. Reprod Sci. (2021) 28:2367–77. doi: 10.1007/s43032-021-00506-5 13 ChadchanSBPopliPAmbatiCRTycksenEHanSJBulunSEet al. Gut microbiota-derived short-chain fatty acids protect against the progression of endometriosis. Life Sci Alliance. (2021) 4:e202101224. doi: 10.26508/lsa.202101224 14 PengLLiZRGreenRSHolzmanIRLinJ. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. (2009) 139:1619–25. doi: 10.3945/jn.109.104638 15 YanHAjuwonKM. Butyrate modifies intestinal barrier function in IPEC-J2 cells through a selective upregulation of tight junction proteins and activation of the Akt signaling pathway. PloS One. (2017) 12:e0179586. doi: 10.1371/journal.pone.0179586 16 ZhangMWangYZhaoXLiuCWangBZhouJ. Mechanistic basis and preliminary practice of butyric acid and butyrate sodium to mitigate gut inflammatory diseases: a comprehensive review. Nutr Res. (2021) 95:1–18. doi: 10.1016/j.nutres.2021.08.007 17 HodgkinsonKEl AbbarFDobranowskiPManoogianJButcherJFigeysDet al. Butyrate's role in human health and the current progress towards its clinical application to treat gastrointestinal disease. Clin Nutr. (2023) 42:61–75. doi: 10.1016/j.clnu.2022.10.024 18 DonohoeDRGargeNZhangXSunWO'ConnellTMBungerMKet al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. (2011) 13:517–26. doi: 10.1016/j.cmet.2011.02.018 19 StillingRMvan de WouwMClarkeGStantonCDinanTGCryanJF. The neuropharmacology of butyrate: the bread and butter of the microbiota-gut-brain axis? Neurochem Int. (2016) 99:110–32. doi: 10.1016/j.neuint.2016.06.011 20 ZhangLLiuCJiangQYinY. Butyrate in energy metabolism: there is still more to learn. Trends Endocrinol Metab. (2021) 32:159–69. doi: 10.1016/j.tem.2020.12.003 21 WenXZhangJXuZLiMDongXDuYet al. Highly expressed lncRNA H19 in endometriosis promotes aerobic glycolysis and histone lactylation. Reproduction. (2024) 168:e240018. doi: 10.1530/rep-24-0018 22 KohADe VadderFKovatcheva-DatcharyPBackhedF. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. (2016) 165:1332–45. doi: 10.1016/j.cell.2016.05.041 23 CanforaEEMeexRCRVenemaKBlaakEE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. (2019) 15:261–73. doi: 10.1038/s41574-019-0156-z 24 DavieJR. Inhibition of histone deacetylase activity by butyrate. J Nutr. (2003) 133:2485S–93S. doi: 10.1093/jn/133.7.2485s 25 ZouYLuQZhengDChuZLiuZChenHet al. Prenatal levonorgestrel exposure induces autism-like behavior in offspring through ERbeta suppression in the amygdala. Mol Autism. (2017) 8:46. doi: 10.1186/s13229-017-0159-3 26 CeradiniDJYaoDGroganRHCallaghanMJEdelsteinDBrownleeMet al. Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice. J Biol Chem. (2008) 283:10930–8. doi: 10.1074/jbc.m707451200 27 YaoDLiHGouYZhangHVlessidisAGZhouHet al. Betulinic acid-mediated inhibitory effect on hepatitis B virus by suppression of manganese superoxide dismutase expression. FEBS J. (2009) 276:2599–614. doi: 10.1111/j.1742-4658.2009.06988.x 28 SomasundaramKEl-DeiryWS. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene. (1997) 14:1047–57. doi: 10.1038/sj.onc.1201002 29 YaoDShiWGouYZhouXYee AwTZhouYet al. Fatty acid-mediated intracellular iron translocation: a synergistic mechanism of oxidative injury. Free Radic Biol Med. (2005) 39:1385–98. doi: 10.1016/j.freeradbiomed.2005.07.015 30 ZhangHLiLChenQLiMFengJSunYet al. PGC1beta regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism. Mol Oncol. (2018) 12:1579–95. doi: 10.1002/1878-0261.12363 31 KongDZhanYLiuZDingTLiMYuHet al. SIRT1-mediated ERβ suppression in the endothelium contributes to vascular aging. Aging Cell. (2016) 15:1092–102. doi: 10.1111/acel.12515 32 KobayashiEHSuzukiTFunayamaRNagashimaTHayashiMSekineHet al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun. (2016) 7:11624. doi: 10.1038/ncomms11624 33 YangCJPengYSSungPCHsiehSY. Protocol for oral fecal gavage to reshape the gut microbiota in mice. STAR Protoc. (2025) 6:103585. doi: 10.1016/j.xpro.2024.103585 34 WangHBWangPYWangXWanYLLiuYC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Dig Dis Sci. (2012) 57:3126–35. doi: 10.1007/s10620-012-2259-4 35 FengYHuangYWangYWangPSongHWangF. Antibiotics induced intestinal tight junction barrier dysfunction is associated with microbiota dysbiosis, activated NLRP3 inflammasome and autophagy. PloS One. (2019) 14:e0218384. doi: 10.1371/journal.pone.0218384 36 ArumugamMRaesJPelletierELe PaslierDYamadaTMendeDRet al. Enterotypes of the human gut microbiome. Nature. (2011) 473:174–80. doi: 10.1038/nature09944 37 ZhangSWangHZhuMJ. A sensitive GC/MS detection method for analyzing microbial metabolites short chain fatty acids in fecal and serum samples. Talanta. (2019) 196:249–54. doi: 10.1016/j.talanta.2018.12.049 38 RamezaniGNorouziAArabshahiSKSSohrabiZZazoliAZSaravaniSet al. Study of medical students' learning approaches and their association with academic performance and problem-solving styles. J Educ Health Promot. (2022) 11:252. doi: 10.4103/jehp.jehp_900_21 39 ReddivariLVeeramachaneniDNRWaltersWALozuponeCPalmerJHewageMKKet al. Perinatal bisphenol A exposure induces chronic inflammation in rabbit offspring via modulation of gut bacteria and their metabolites. mSystems. (2017) 2:e00093-17. doi: 10.1128/msystems.00093-17 40 FengLChenSZhangLQuWChenZ. Bisphenol A increases intestinal permeability through disrupting intestinal barrier function in mice. Environ pollut. (2019) 254:112960. doi: 10.1016/j.envpol.2019.112960 41 FanYPedersenO. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. (2021) 19:55–71. doi: 10.1038/s41579-020-0433-9 42 ViscontiALe RoyCIRosaFRossiNMartinTCMohneyRPet al. Interplay between the human gut microbiome and host metabolism. Nat Commun. (2019) 10:4505. doi: 10.1038/s41467-019-12476-z 43 CananiRBCostanzoMDLeoneLPedataMMeliRCalignanoA. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. (2011) 17:1519–28. doi: 10.3748/wjg.v17.i12.1519 44 Parada VenegasDDe la FuenteMKLandskronGGonzalezMJQueraRDijkstraGet al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front Immunol. (2019) 10:277. doi: 10.3389/fimmu.2019.00277 45 ZhangDTangZHuangHZhouGCuiCWengYet al. Metabolic regulation of gene expression by histone lactylation. Nature. (2019) 574:575–80. doi: 10.1038/s41586-019-1678-1 Summary

Keywords

bisphenol A, butyrate, developmental programming, endometriosis, gut microbiota, prenatal exposure Citation Li D, Zhang T, Liu X, Luo S, Huang Z, Huang L, Yao P and Zeng L (2026) Fecal microbiota transplantation and butyrate attenuate prenatal BPA exposure-mediated endometriosis susceptibility through a gut–immune–metabolic axis. Front. Endocrinol. 17:1987816. doi: 10.3389/fendo.2026.1987816 Received 03 September 2026 Revised 19 October 2026 Accepted 23 October 2026 Published 17 November 2026 Volume 17 - 2026 Edited by Abhishek Gupta, Autonomous State Medical College, India Reviewed by Yu Pi, Chinese Academy of Agricultural Sciences, China Shuaijun Lv, Southern Medical University, China Updates Copyright © 2026 Li, Zhang, Liu, Luo, Huang, Huang, Yao and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. *Correspondence: Paul Yao, [email protected]; Liqin Zeng, [email protected] †These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (45)

Source provenance

openalex
last seen: 2026-11-20T06:09:37.170340+00:00
License: CC0 · commercial use OK